Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of EP-0170T(I) in patients with mild to moderate essential hypertension inadequately controlled after 4 weeks of monotherapy
CTR20252156Phase 3Completed
- Sponsor
- Shuode Pharmaceutical
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacubitril + valsartan in essential hypertension, sponsored by Shuode Pharmaceutical. Started Jul 2025; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20252156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252156.